Immediate Impact
1 by Nobel laureates 59 standout
Citing Papers
Targeting ROS in cancer: rationale and strategies
2024 Standout
Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer
2024 Standout
Works of S.-B. Kim being referenced
Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)
2023
Overall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| S.-B. Kim | 213 | 77 | 27 | 101 | 20 | 295 | |
| Lucas Basler | 165 | 119 | 19 | 128 | 19 | 285 | |
| Martina Vrankar | 224 | 210 | 23 | 77 | 21 | 335 | |
| Prabhsimranjot Singh | 113 | 136 | 47 | 42 | 26 | 311 | |
| Ingrid Garberis | 137 | 72 | 42 | 104 | 14 | 239 | |
| Kevin Lee Min Chua | 130 | 198 | 37 | 63 | 30 | 316 | |
| Adam Diehl | 215 | 69 | 36 | 26 | 15 | 290 | |
| Christine H. Feng | 80 | 113 | 53 | 78 | 26 | 310 | |
| Xuejun Ma | 203 | 62 | 45 | 30 | 25 | 335 | |
| Laura Faivre | 181 | 156 | 56 | 38 | 16 | 302 | |
| Valentina Magri | 196 | 60 | 17 | 54 | 27 | 324 |
All Works
Loading papers...